No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Tuesday, October 28, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

Trump plans a hefty tax on imported drugs, risking higher prices and shortages

by TheAdviserMagazine
2 months ago
in Business
Reading Time: 4 mins read
A A
Trump plans a hefty tax on imported drugs, risking higher prices and shortages
Share on FacebookShare on TwitterShare on LInkedIn



WASHINGTON (AP) — President Donald Trump has plastered tariffs on products from almost every country on earth. He’s targeted specific imports including autos, steel and aluminum.

But he isn’t done yet.

Trump has promised to impose hefty import taxes on pharmaceuticals, a category of products he’s largely spared in his trade war. For decades, in fact, imported medicine has mostly been allowed to enter the United States duty free.

That’s starting to change. U.S. and European leaders recently detailed a trade deal that includes a 15% tariff rate on some European goods brought into the United States, including pharmaceuticals. Trump is threatening duties of 200% more on drugs made elsewhere.

“Shock and awe’’ is how Maytee Pereira of the tax and consulting firm PwC describes Trump’s plans for drugmakers. “This is an industry that’s going from zero (tariffs) to the potentiality of 200%.’’

Trump has promised Americans he’ll lower their drug costs. But imposing stiff pharmaceutical tariffs risks the opposite and could disrupt complex supply chains, drive cheap foreign-made generic drugs out of the U.S. market and create shortages.

“A tariff would hurt consumers most of all, as they would feel the inflationary effect … directly when paying for prescriptions at the pharmacy and indirectly through higher insurance premiums,’’ Diederik Stadig, a healthcare economist with the financial services firm ING, wrote in a commentary last month, adding that lower-income households and the elderly would feel the greatest impact.

The threat comes as Trump also pressures drugmakers to lower prices in the United States. He recently sent letters to several companies telling them to develop a plan to start offering so-called most-favored nation pricing here.

But Trump has said he’d delay the tariffs for a year or a year and a half, giving companies a chance to stockpile medicine and shift manufacturing to the United States — something some have already begun to do.

Leerink Partners analyst David Risinger said in a July 29 note that most drugmakers have already increased drug product imports and may carry between six and 18 months of inventory in the U.S.

Jefferies analyst David Windley said in a recent research note that tariffs that don’t kick in until the back half of 2026 may not be felt until 2027 or 2028 due to stockpiling.

Moreover, many analysts suspect Trump will settle for a tariff far lower than 200%. They also are waiting to see whether any tariff policy includes an exemption for certain products like low-margin generic drugs.

Still, Stadig says, even a 25% levy would gradually raise U.S. drug prices by 10% to 14% as the stockpiles dwindle.

In recent decades, drugmakers have moved many operations overseas – to take advantage of lower costs in China and India and tax breaks in Ireland and Switzerland. As a result, the U.S. trade deficit in medicinal and pharmaceutical products is big — nearly $150 billion last year.

The COVID-19 experience – when countries were desperate to hang onto their own medicine and medical supplies — underscored the dangers of relying on foreign countries in a crisis, especially when a key supplier is America’s geopolitical rival China.

In April, the administration started investigating how importing drugs and pharmaceutical ingredients affects national security. Section 232 of the Trade Expansion Act of 1962 permits the president to order tariffs for the sake of national security.

Marta Wosińska, a health policy analyst at the Brookings Institution, says there is a role for tariffs in securing U.S. medical supplies. The Biden administration, she noted, successfully taxed foreign syringes when cheap Chinese imports threatened to drive U.S. producers out of business.

Trump has bigger ideas: He wants to bring pharmaceutical factories back to the United States, noting that U.S.-made drugs won’t face his tariffs.

Drugmakers are already investing in the United States.

The Swiss drugmaker Roche said in April that it will invest $50 billion in expanding its U.S. operations. Johnson & Johnson will spend $55 billion within the United States in the next four years. CEO Joaquin Duato said recently that the company aims to supply drugs for the U.S. market entirely from sites located there.

But building a pharmaceutical factory in the United States from scratch is expensive and can take several years.

And building in the U.S. wouldn’t necessarily protect a drugmaker from Trump’s tariffs, not if the taxes applied to imported ingredients used in the medicine. Jacob Jensen, trade policy analyst at the right-leaning American Action Forum, notes that “97% of antibiotics, 92% of antivirals and 83% of the most popular generic drugs contain at least one active ingredient that is manufactured abroad.’’

“The only way to truly protect yourself from the tariffs would be to build the supply chain end to end in the United States,’’ Pereira said.

Brand-name drug companies have fat profit margins that provide flexibility to make investments and absorb costs as Trump’s tariffs begin. Generic drug manufacturers do not.

Some may decide to leave the U.S. market rather than pay tariffs. That could prove disruptive: Generics account for 92% of U.S. retail and mail-order pharmacy prescriptions.

A production pause at a factory in India a couple years ago led to a chemotherapy shortage that disrupted cancer care. “Those are not very resilient markets,” Brookings’ Wosińska said. “If there’s a shock, it’s hard for them to recover.”

She argues that tariffs alone are unlikely to persuade generic drug manufacturers to build U.S. factories: They’d probably need government financing.

“In an ideal world, we would be making everything that’s important only in the U.S.,’’ Wosińska said. “But it costs a lot of money … We have offshored so much of our supply chains because we want to have inexpensive drugs. If we want to reverse this, we would really have to redesign our system … How much are we willing to spend?”

___

Murphy reported from Indianapolis. AP Health Writer Matthew Perrone contributed to this report.



Source link

Tags: drugsheftyhigherimportedplansPricesRiskingShortagestaxTrump
ShareTweetShare
Previous Post

Of Property Rights, Civil Society, and Shampoo

Next Post

OpenAI staffer left America for Sweden because of Trump’s presidency

Related Posts

edit post
Wizz Air uncompromising on demands for Israel hub

Wizz Air uncompromising on demands for Israel hub

by TheAdviserMagazine
October 28, 2025
0

Senior officials from Israel’s Ministry of Transport have traveled to Hungary for intensive talks with top Wizz Air executives...

edit post
Trump says he is prepared to send ‘more than the National Guard’ into US cities

Trump says he is prepared to send ‘more than the National Guard’ into US cities

by TheAdviserMagazine
October 28, 2025
0

President Donald Trump told U.S. troops assembled in Japan on Tuesday that he was prepared to send "more than the...

edit post
Nokia shares jump on B Nvidia investment to grow AI networking, cloud footprint (NVDA:NASDAQ)

Nokia shares jump on $1B Nvidia investment to grow AI networking, cloud footprint (NVDA:NASDAQ)

by TheAdviserMagazine
October 28, 2025
0

BING-JHEN HONG/iStock Editorial via Getty ImagesTop chipmaker Nvidia (NASDAQ:NVDA) is investing $1B in Nokia (NYSE:NOK)—the former Finnish cellphone giant, which...

edit post
Amazon is pushing out thousands of workers into a job market that suddenly isn’t hiring

Amazon is pushing out thousands of workers into a job market that suddenly isn’t hiring

by TheAdviserMagazine
October 28, 2025
0

Amazon will cut about 14,000 corporate jobs as the online retail giant ramps up spending on artificial intelligence while cutting...

edit post
Secondary rounds in tech sector make a comeback

Secondary rounds in tech sector make a comeback

by TheAdviserMagazine
October 28, 2025
0

Secondary rounds in the tech industry - employees and founders selling shares as part of bringing new investors into...

edit post
JPMorgan boss Jamie Dimon renews return-to-office push

JPMorgan boss Jamie Dimon renews return-to-office push

by TheAdviserMagazine
October 28, 2025
0

JPMorgan Chase boss Jamie Dimon is doubling down on pushing workers back into the office despite a recent petition from...

Next Post
edit post
OpenAI staffer left America for Sweden because of Trump’s presidency

OpenAI staffer left America for Sweden because of Trump's presidency

edit post
*HOT* Factor Meal Discount: 0 off + Free Shipping!!

*HOT* Factor Meal Discount: $130 off + Free Shipping!!

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Another Violent Outburst – Democrats Inciting Civil Unrest

Another Violent Outburst – Democrats Inciting Civil Unrest

October 24, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
Ray Dalio says a risky AI market bubble is forming, but may not pop until the Fed tightens

Ray Dalio says a risky AI market bubble is forming, but may not pop until the Fed tightens

0
edit post
Wizz Air uncompromising on demands for Israel hub

Wizz Air uncompromising on demands for Israel hub

0
edit post
Estate Planning Myths That Can Haunt Families

Estate Planning Myths That Can Haunt Families

0
edit post
Dollar mixed as investors eye central bank decisions, trade talks

Dollar mixed as investors eye central bank decisions, trade talks

0
edit post
Unlocking Stock Market Success: Why You Should Embrace the Skew

Unlocking Stock Market Success: Why You Should Embrace the Skew

0
edit post
Why Republics Will Collapse | Armstrong Economics

Why Republics Will Collapse | Armstrong Economics

0
edit post
Ray Dalio says a risky AI market bubble is forming, but may not pop until the Fed tightens

Ray Dalio says a risky AI market bubble is forming, but may not pop until the Fed tightens

October 28, 2025
edit post
Wizz Air uncompromising on demands for Israel hub

Wizz Air uncompromising on demands for Israel hub

October 28, 2025
edit post
Dogecoin Price Hasn’t Begun Its 3rd Wave Yet, ATH Above alt=

Dogecoin Price Hasn’t Begun Its 3rd Wave Yet, ATH Above $0.8 Still In The Cards

October 28, 2025
edit post
Trump says he is prepared to send ‘more than the National Guard’ into US cities

Trump says he is prepared to send ‘more than the National Guard’ into US cities

October 28, 2025
edit post
183 Million Credentials Stolen, Including Millions of Gmail Logins. Google Says Reports Are ‘Greatly Exaggerated.’ Are Your Details Safe?

183 Million Credentials Stolen, Including Millions of Gmail Logins. Google Says Reports Are ‘Greatly Exaggerated.’ Are Your Details Safe?

October 28, 2025
edit post
Nokia shares jump on B Nvidia investment to grow AI networking, cloud footprint (NVDA:NASDAQ)

Nokia shares jump on $1B Nvidia investment to grow AI networking, cloud footprint (NVDA:NASDAQ)

October 28, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • Ray Dalio says a risky AI market bubble is forming, but may not pop until the Fed tightens
  • Wizz Air uncompromising on demands for Israel hub
  • Dogecoin Price Hasn’t Begun Its 3rd Wave Yet, ATH Above $0.8 Still In The Cards
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.